Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$406B
P/E (fwd)
16×
Div yield
3.3%
EPS (adj, '26E)
~$14.5
Revenue (FY25)
$61.1B
Rev. growth
+8.6%
Rev. guide ('26)
$67.3B
Free cash flow
~$20B
In plain English
AbbVie is the drugmaker that grew out of Humira — and then engineered its life beyond it. Two immunology successors, Skyrizi and Rinvoq, now out-earn Humira at its peak, while a ~$63B takeover of Allergan bolted on Botox, a global aesthetics franchise and a deep neuroscience book. It is a serial acquirer that turns scientific bets and acquisition debt into a diversified portfolio across immunology, neuroscience, oncology and aesthetics.
In simple terms
What AbbVie really sells
AbbVie is the drugmaker that grew out of Humira — and then engineered its life beyond it. Two immunology successors, Skyrizi and Rinvoq, now out-earn Humira at its peak, while a ~$63B takeover of Allergan bolted on Botox, a global aesthetics franchise and a deep neuroscience book. It is a serial acquirer that turns scientific bets and acquisition debt into a diversified portfolio across immunology, neuroscience, oncology and aesthetics.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.